Opthea discontinues COAST and ShORe sozinibercept combination therapy trials

News
Article

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

An image of a person pressing a computer shutdown button, superimposed digitally over the image. Concept for clinical trial discontinuation. Image credit: ©natali_mis – stock.adobe.com

Opthea is assessing its rights and obligations under its Development Funding Agreement with investors and other stakeholders. Image credit: ©natali_mis – stock.adobe.com

Opthea has made the decision to discontinue its COAST and ShORe trials in wet age-related macular degeneration (AMD) following the announcement that the COAST trial failed to meet its primary endpoint.

In addition to announcing the termination of ShORe, the company also accelerated topline results from the trial showing that it, too, failed to meet its primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52. The global ShORe phase 3 trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every 4 or 8 weeks in combination with 0.5 mg ranibizumab every 4 weeks, as per label, versus 0.5 mg ranibizumab monotherapy.

Results from the trial showed that participants receiving sozinibercept combination therapy with a dosing regimen of every 4 weeks (n=301) or every 8 weeks (n=301) achieved a mean change in BCVA of 13.3 or 12.9 letters from baseline to week 52, respectively, versus 14.2 letters with ranibizumab monotherapy (n=299, P-values of 0.35 and 0.19, respectively). In the overall population, participants receiving sozinibercept combination therapy with a dosing regimen of every 4 weeks (n=328) or every 8 weeks (n=326) achieved a mean change in BCVA of 13.3 and 12.6 letters from baseline to week 52, respectively, versus 14.3 letters with ranibizumab monotherapy (n=331; P-values of 0.32 and 0.09, respectively).

Frederic Guerard, PharmD, CEO of Opthea, commented on the decision to discontinue the trials in a press release from the company.

“We are disappointed that COAST and ShORe did not demonstrate the improvements in vision with sozinibercept combination therapy compared to standard of care that we had hoped for,” said Guerard. “We are grateful to all patients, clinical investigators and their staff around the world who participated in the sozinibercept Phase 3 clinical program, and for their contributions in investigating new treatments for wet AMD.”

As previously reported, Opthea has been assessing its rights and obligations under its Development Funding Agreement (DFA) with the investors under the DFA, among others. The company updated this by saying Opthea and DFA Investors agreed to discontinue the development of sozinibercept in wet AMD with immediate effect, and that this decision did not constitute a termination event under the DFA resulting in any amount payable by Opthea. A termination event would cause Opthea to pay investors up to four times the amounts paid to the company under the DFA.

The company did note, however, that it remains possible under the DFA, in certain circumstances upon or following termination of the DFA, Opthea could become required to pay a multiple of the amount funded by the DFA Investors that would have a “material adverse impact on the solvency of the company.” Termination can be triggered by a range of events including Opthea’s insolvency, in which case Opthea will be obligated to pay a multiple of the amounts funded by the DFA Investors.

The company noted that it is currently relying on the "safe harbour" provisions in section 588GA of the Corporations Act 2001 (Cth) and that trading in Opthea’s listed securities will be suspended by ASX under ASX Listing Rule 17.3 until the company is in a position to provide an announcement to the market providing more clarity on these issues and the impact on its financial position.

References:

  1. Opthea announces decision to discontinue wet AMD trials. News release. Opthea. Published March 31, 2025. Accessed March 31, 2025. https://ir.opthea.com/news-releases/news-release-details/opthea-announces-decision-discontinue-wet-amd-trials-0
  2. Harp M. Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint. Ophthalmology Times. Published March 24, 2025. Accessed March 31, 2025. https://www.ophthalmologytimes.com/view/opthea-phase-3-clinical-trial-coast-in-patients-with-wet-age-related-macular-degeneration-fails-to-meet-primary-endpoint

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.